The protein engineering market is estimated to be valued at USD 3.61 Billion in 2024 and is expected to reach USD 10.4 Billion by 2031, growing at a compound annual growth rate (CAGR) of 16.3% from 2024 to 2031.
Figure 1. Protein Engineering Market Share (%), By Region, 2024
Protein engineering is the process of developing useful proteins through rational or evolutionary design. It employs techniques, such as site-directed mutagenesis, chimeric construction, and random mutagenesis, to develop desired protein structures and functions. The global protein engineering market offers significant opportunities as it enables downstream applications in industries including biopharmaceuticals, industrial enzymes, food and beverages, and academics. Major proteins targeted in this field include antibodies, hormones, and vaccines. Advancements in gene synthesis, computational tools, and structural biology have accelerated research in this field.
Market Dynamics:
The global protein engineering market is primarily driven by factors such as the growth of the biopharmaceutical industry, increasing research activities in synthetic biology, and advent of innovative technologies like gene synthesis. Biopharmaceutical companies are actively utilizing techniques such as directed evolution and computational design to develop therapeutic antibodies, enzymes, and proteins. However, factors such as high costs associated with protein engineering techniques and ethical issues pertaining to synthetic biology pose challenges to the market. Growing protein therapeutics pipeline and collaborations between academic and industrial players present new opportunities for market expansion.
Key Features of the Study:
- This report provides an in-depth analysis of the global protein engineering market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global protein engineering market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Thermo Fisher Scientific, Agilent Technologies, Waters Corporation, Bio-Rad Laboratories, and Bruker Corporation.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global protein engineering market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global protein engineering market.
Detailed Segmentation-
- By Product Type
- Modified Enzymes
- Insulin
- Monoclonal Antibodies
- Coagulation Factors (Blood Factors + Tissue Plasminogen)
- Vaccines
- Growth Factors (Hormones + Cytokine)
- Other Product Types
- By Technology
- Irrational Protein Design
- Rational Protein Design
- By End User
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations (CRO)
- Academic Institutions
- Others
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Agilent Technologies Inc.
- Amgen Inc.
- Bruker Corporation
- Bio-Rad Laboratories Inc.
- Eli Lilly and Company
- Merck KGaA
- Novo Nordisk AS
- PerkinElmer Inc.
- Thermo Fisher Scientific Inc.
- Waters Corporation
- GenScript Biotech Corporation
- GE Healthcare
- Absci
- ElevateBio
- Ingenza
- Anima Biotech
- Ventus Therapeutics
- Aether Biomachines, Inc.